Ziv-aflibercept in metastatic colorectal cancer
Biologics: Targets & Therapy, 2013 Anuj Patel, Weijing Sun Division of Hematology-Oncology, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA Abstract: The combination of cytotoxic chemotherapy and antiangiogenic agents has become
Patel A, Sun W
doaj
Clinical Ophthalmology, 2023 Suthasinee Sinawat,1,2 Suthasinee Hemanak,1 Kwanchanok Chanthowong,1 Supat Sinawat,3 Yosanan Yospaiboon1,2 1Department of Ophthalmology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand; 2KKU Eye Center, Khon Kaen University, Khon Kaen ...
Sinawat S +4 more
doaj
Single pivotal trials with few corroborating characteristics were used for FDA approval of cancer therapies [PDF]
, 2019 Background and objective Novel cancer therapies are often approved with evidence from a single pivotal trial alone. There are concerns about the credibility of this evidence.
Arnav, A +9 more
core +2 more sources
Indian Journal of Ophthalmology, 2018 A 64-year-old male patient presented to the clinic with diminished vision in his right eye for the past 2 years. Examination revealed a best-corrected visual acuity (BCVA) of counting fingers at 1 m with a scarred choroidal neovascular membrane (CNVM) in
Vishal Govindhari, Jay Chhablani
doaj +1 more source
A systematic review of the cost-effectiveness of anti-VEGF drugs for the treatment of diabetic retinopathy [PDF]
Background: Non-proliferative and proliferative diabetic retinopathy are common complications of diabetes and a major cause of sight loss. Anti-vascular endothelial growth factor drugs represent a treatment option for people with diabetic retinopathy and
Bojke L +11 more
core +1 more source
Delhi Journal of OphthalmologyWe report the case of a 62-year-old female diagnosed with Type 2A, Stage 5 macular telangiectasia (MacTel). The right eye showed a scarred choroidal neovascular membrane (CNVM) while the left eye had an active CNVM, confirmed with optical coherence ...
Mohd Azaz Quraishi +5 more
doaj +1 more source
One-year outcome of intravitreal ziv-aflibercept therapy for non-responsive neovascular age-related macular degeneration [PDF]
, 2018 Aim To evaluate 12-month outcome of intravitreal ziv-aflibercept (IVZ) therapy in eyes with neovascular age-related macular degeneration (nAMD) that are non-responsive to bevacizumab and ranibizumab.
Agarwal, Komal +3 more
core +1 more source
Intravitreal Ziv-Aflibercept versus Bevacizumab for Naïve Central Retinal Vein Occlusion with Macular Edema: An Interim Analysis of a Randomized Non-Inferiority Trial. [PDF]
Clin Ophthalmol, 2023 Sinawat S +4 more
europepmc +1 more source
Ramucirumab, another anti-angiogenic agent for metastatic colorectal cancer in second-line setting - Its impact on clinical practice [PDF]
, 2015 The recent FDA approval of ramucirumab (RAISE trial) has added a third agent to our existing armamentarium of angiogenesis inhibitors (bevacizumab and ziv-aflibercept) for the second-line treatment of metastatic colorectal cancer, which may have some ...
Goel, G, Sun, W
core +2 more sources
Seguridad del uso intravítreo de 2 mg de ziv-aflibercept a corto plazo en diferentes patologías retinianas [PDF]
, 2019 Abel Ramón-Concepción +8 more
openalex +1 more source